Tenapanor hydrochloride is a Small Molecule owned by Ardelyx, and is involved in 33 clinical trials, of which 29 were completed, 3 are ongoing, and 1 is planned.

Tenapanor is a locally acting inhibitor of the sodium/hydrogen exchanger 3 (NHE3), an antiporter expressed on the apical surface of the small intestine and colon primarily responsible for the absorption of dietary sodium

Tenapanor acts as a NHE3 inhibitor. NHE3 is localized to the apical membrane and play important roles in intestinal Na+ absorption with varying activities in different segments of the gastrointestinal tract. The Na+/H+ exchanger 3 mediates the majority of the NaCl and NaHCO3 absorption in the mammalian ileum. In normal digestive physiology, Inhibition of NHE3 regulation leads to inhibition of Na+ absorption, resulting in decreased water absorption and diarrhea.

The revenue for Tenapanor hydrochloride is expected to reach a total of $5.7bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Tenapanor hydrochloride NPV Report.

Tenapanor hydrochloride is originated and owned by Ardelyx. Kyowa Kirin is the other company associated in development or marketing of Tenapanor hydrochloride.

Tenapanor hydrochloride Overview

Tenapanor hydrochloride (Ibsrela) belongs to 4-phenyltetrahydroisoquinolines. It is formulated as tablets for oral route of administration. Ibsrela is indicated for the treatment of  irritable bowel syndrome with constipation (IBS-C) in adults.

Tenapanor is under development for the treatment of hyperphosphatemia in hemodialysis patients, irritable bowel syndrome and hyperphosphatemia in patients with end-stage renal disease. The drug candidate was also under development for the treatment of chronic kidney disease patients with type 2 diabetes mellitus and albuminuria.

Ardelyx Overview

Ardelyx, is a pharmaceutical company. It is a developer of small molecule therapeutics for treatment of cardio-renal, gastrointestinal and metabolic disorders. The company offers products that include tenapanor, and RDX013. Its products are used for hyperphosphatemia in patients with end-stage renal disease; constipation-predominant irritable bowel syndrome; and hyperkalemia, in chronic kidney disease patients. Ardelyx develops proprietary drug discovery and design platform to discover and design novel drug candidates such as tenapanor and others. The company works in partnership with pharmaceutical and biotechnology companies to discover small molecule drugs. Ardelyx is headquartered in Fremont, California, the US. Ardelyx, is a pharmaceutical company. It is a developer of small molecule therapeutics for treatment of cardio-renal, gastrointestinal and metabolic disorders. The company offers products that include tenapanor, and RDX013. Its products are used for hyperphosphatemia in patients with end-stage renal disease; constipation-predominant irritable bowel syndrome; and hyperkalemia, in chronic kidney disease patients. Ardelyx develops proprietary drug discovery and design platform to discover and design novel drug candidates such as tenapanor and others. The company works in partnership with pharmaceutical and biotechnology companies to discover small molecule drugs. Ardelyx is headquartered in Fremont, California, the US.

Quick View – Tenapanor hydrochloride

Report Segments
  • Innovator (NME)
Drug Name
  • Tenapanor hydrochloride
Administration Pathway
  • Oral
Therapeutic Areas
  • Gastrointestinal
  • Genito Urinary System And Sex Hormones
  • Nutritional Disorders
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.